Latigo Biotherapeutics Inc.

Latigo Biotherapeutics, Inc. (NASDAQ: LTGO - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month price

Phase 3 bunionectomy and open-label safety trials of onzotrigine remain on track for initiation with topline results expected in the second half of 2027

Todd N. Smith, a seasoned executive with deep experience commercializing pain therapies, appointed as president and chief executive officer to lead Latigo through planned late-stage development and commercialization of the Company's pipeline of non-opioid pain treatment programs

THOUSAND OAKS, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced that management will participate in the following investor conferences: Guggenheim 3 rd Annual Healthcare Innovation Conference – Boston, MA Fireside chat on Tuesday, November 10, 2026, at 8:30 a.m.

Latigo Biotherapeutics is undervalued below IPO, with onzotrigine showing superior efficacy to Vertex's Journavx in acute pain. LTGO leverages Vertex's market groundwork, has pivotal-eligible Phase 2 data, and is funded into 2029, reducing near-term financing risk. Onzotrigine's Phase 3 bunionectomy trial is the key binary event; positive results could drive significant upside versus current market expectations.

Latigo Biotherapeutics, Inc. (NASDAQ: LTGO - Get Free Report) shares hit a new 52-week low on Thursday. The stock traded as low as $15.27 and last traded at $15.52, with a volume of 241512 shares trading hands. The stock had previously closed at $16.26. Wall Street Analyst Weigh In A number of equities analysts have recently

Latigo Biotherapeutics' (NASDAQ: LTGO - Get Free Report) quiet period will expire on Wednesday, September 16th. Latigo Biotherapeutics had issued 19,200,000 shares in its public offering on August 7th. The total size of the offering was $345,600,000 based on an initial share price of $18.00. During Latigo Biotherapeutics' quiet period, insiders and any underwriters that worked

Completed upsized initial public offering, including full exercise of the underwriters' option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund operations into 2029 The New England Journal of Medicine published positive onzotrigine (previously referred to as LTG-001) abdominoplasty clinical trial results in moderate-to-severe acute pain Expanded leadership team with appointment of Naomi Lowy, M.D., former deputy director of the…

Latigo Biotherapeutics (NASDAQ:LTGO) arrived on public markets with the kind of reception biotech bankers dream about.

Latigo Biotherapeutics, Inc. (NASDAQ: LTGO - Get Free Report) Director James Tananbaum bought 140,000 shares of the business's stock in a transaction that occurred on Monday, August 10th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the completion of the transaction, the director owned 2,008,024

Latigo Biotherapeutics, Inc. (NASDAQ: LTGO - Get Free Report) major shareholder Foresite Capital Management V, bought 140,000 shares of Latigo Biotherapeutics stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the acquisition, the insider directly owned 2,008,024 shares